AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36266481
Drug: 10-ml 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-ml 0.5% bupivacaine without epinephrine
Trial: 36266481
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of 0.9% saline (control)
Trial: 32723753
Drug: Gradual antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual antipsychotic reduction and discontinuation
Trial: 35868433
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg NVCM intravenously every 12 h and 16 mg NVCM intrathecal administration every 24 h
Trial: 35868433
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg NVCM intravenously every 12 h (Control)
Trial: 33649919
Drug: Initial use
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial use of oral sodium alginate (arm A)
Trial: 33649919
Drug: Late use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late use of oral sodium alginate (arm B)
Trial: 32723991
Drug: Two-weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two-weekly docetaxel for 8 cycles
Trial: 35411939
Drug: SOC +
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SOC + AAP (Abiraterone acetate 1000 mg + Prednisolone 5 mg)
Trial: 35411939
Drug: SOC-alone (Standard-of-care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC-alone (Standard-of-care androgen deprivation therapy)
Trial: 32639561
Drug: BT to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BT to Zolpidem (second-stage therapy)
Trial: 32639561
Drug: BT to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BT to Cognitive Therapy (CT) (second-stage therapy)
Trial: 32639561
Drug: Zolpidem to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem to Trazodone (second-stage therapy)
Trial: 33161159
Drug: Newly-prescribed medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newly-prescribed medical therapy
Trial: 33321778
Drug: Co-induction technique
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-induction technique (4% sevoflurane followed by 0.75 mg/kg propofol)
Trial: 33321778
Drug: Sevoflurane (8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane (8% with 100% oxygen at 8 L/min)
Trial: 34324100
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg dexamethasone intravenously (IV) preoperatively
Trial: 34324100
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg dexamethasone from a nebulizer mask preoperatively
Trial: 34143199
Drug: Sonic activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonic activation of desensitizing agent (DA) containing 5% potassium nitrate and 2% sodium fluoride, activated for 30 seconds per tooth.
Trial: 34143199
Drug: Desensitizing agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desensitizing agent (DA) without sonic activation, applied for 10 minutes.
Trial: 34143199
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (SA and noSA)
Trial: 36445624
Drug: Genotype-guided (GG)
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-guided (GG) escalation of P2Y12 inhibitor therapy post PCI
Trial: 34510193
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic Acid (FA) supplementation (5 mg/d for 12 weeks)
Trial: 35841243
Drug: Adenosine Triphosphate
RxNorm normalized name: Adenosine triphosphate
DrugBank: ATP (DB00171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine Triphosphate (ATP) infusion
Trial: 36327309
Drug: Rectal progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rectal progesterone suppository
Trial: 34887528
Drug: Intranasal 24IU
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal 24IU oxytocin
Trial: 34016346
Drug: Ice slurry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ice slurry (4 g⋅kg ‐1 body weight, 0.5 °C)
Trial: 35779189
Drug: NX210 (0.4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NX210 (0.4, 1.25, 2.5, 5, and 10 mg/kg)
Trial: 35422611
Drug: Lidocaine infusion
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine infusion (1.5 mg/kg bolus before anesthesia induction, followed by 2.0 mg/kg/h continuous infusion until end of surgery)
Trial: 32863142
Drug: Chloride-rich intravenous
RxNorm normalized name: CHLORIDE
DrugBank: Chloride ion (DB14547)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloride-rich intravenous fluid (0.9% saline)
Trial: 36579554
Drug: US-guided corticosteroid
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-guided corticosteroid injections combined with a personalized rehabilitation program (Group A; n: 19)
Trial: 36579554
Drug: US-guided corticosteroid
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-guided corticosteroid injections alone (Group B; n: 18)
Trial: 35107855
Drug: Ayahuasca (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayahuasca (average 1.58 mg/ml DMT) in healthy volunteers
Trial: 35107855
Drug: Ayahuasca (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayahuasca (average 0.680 mg/ml DMT) in volunteers with SAD
Trial: 32455019
Drug: Daily ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily ingestion of 60 mg iron and 0.4 mg folic acid
Trial: 32779607
Drug: Silane coupling
RxNorm normalized name: silane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silane coupling agent application (SL)
Trial: 32779607
Drug: No surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No surface treatment (C)
Trial: 33856973
Drug: Mindfulness-based schema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based schema (MBS) therapy
Trial: 36060196
Drug: 1WS (once-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1WS (once-weekly support by specialized therapists)
Trial: 36060196
Drug: 1W/1BD-S (once-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1W/1BD-S (once-weekly support supplemented with one-business-day response to emails)
Trial: 36060196
Drug: 1WC (once-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1WC (once-weekly support by therapists in community clinics)
Trial: 36328912
Drug: Active distraction
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active distraction (tablet)
Trial: 35485835
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Social Anxiety (CBT-SA)
Trial: 32835417
Drug: Zoledronate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoledronate treatment
Trial: 32739319
Drug: XP‐RT (adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XP‐RT (adjuvant concurrent chemo‐radiotherapy)
Trial: 32739319
Drug: XP (chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XP (chemotherapy alone)
Trial: 32396700
Drug: Oral PrEP
RxNorm normalized name: Iron bivalent, oral preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral PrEP initiation
Trial: 34282831
Drug: Needle-assisted injections
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle-assisted injections
Trial: 34282831
Drug: Cannula-assisted injections
RxNorm normalized name: CANNULA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannula-assisted injections
Trial: 32438301
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (200 mL of inert solution)
Trial: 34853395
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose vitamin D3
Trial: 35460725
Drug: 20% albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% albumin (0.5-1.0 g/kg over 3 hours)
Trial: 35460725
Drug: Plasmalyte (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmalyte (30 ml/kg over 3 hours)
Trial: 33399254
Drug: Abemaciclib added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib added to adjuvant endocrine therapy
Trial: 33399254
Drug: Adjuvant endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant endocrine therapy alone
Trial: 33481463
Drug: Telehealth exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telehealth exercise intervention (functional circuit exercise training via videoconferencing, 3 times weekly for 12 weeks)
Trial: 33853731
Drug: Full-dose almonds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose almonds (73±5 g/d)
Trial: 33853731
Drug: Half-dose almonds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose almonds (38±3 g/d) plus half-dose muffins
Trial: 32494210
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (10 sessions over 3 weeks)
Trial: 35080256
Drug: Daclatasvir 60
RxNorm normalized name: daclatasvir 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir 60 mg plus alfosbuvir 400 mg daily (Cohort A)
Trial: 35080256
Drug: Daclatasvir 60
RxNorm normalized name: daclatasvir 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir 60 mg plus alfosbuvir 600 mg daily (Cohort B)
Trial: 35080256
Drug: Daclatasvir 60
RxNorm normalized name: daclatasvir 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir 60 mg plus alfosbuvir 800 mg daily (Cohort C)
Trial: 34871153
Drug: Ciclesonide (CIC)
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclesonide (CIC) 40, 80, or 160 µg/day
Trial: 34871153
Drug: Ciclesonide (CIC)
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclesonide (CIC) 160 µg/day
Trial: 34871153
Drug: Ciclesonide (CIC)
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclesonide (CIC) 80 or 160 µg/day
Trial: 34265236
Drug: Ivermectin 12
RxNorm normalized name: Ivermectin 12 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin 12 mg on day 1 and 2 post enrolment
Trial: 35553398
Drug: Insufficient maternal
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insufficient maternal vitamin D (< 50 nmol/l) during gestational weeks 18-22
Trial: 35553398
Drug: Sufficient maternal
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sufficient maternal vitamin D (≥ 50 nmol/l) during gestational weeks 18-22
Trial: 34554201
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy (fluorouracil dosing every 2 weeks)
Trial: 33865361
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (50,000 IU/week) plus Magnesium (6 mg/kg/day)
Trial: 36209731
Drug: Monterizine (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monterizine (combination of montelukast and levocetirizine)
Trial: 33762421
Drug: IV metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV metoclopramide 20 mg + diphenhydramine 25 mg (M + D)
Trial: 33369462
Drug: Oral mefenamic
RxNorm normalized name: meclofenamate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mefenamic acid (500 mg) 30 minutes before procedure
Trial: 33369462
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical tablet) 30 minutes before operation
Trial: 35687793
Drug: OC‐01 VNS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC‐01 VNS 0.03 mg
Trial: 35687793
Drug: CsA 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA 0.05% ophthalmic emulsion
Trial: 33628014
Drug: 0.5 μg·kg‐1·h‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 μg·kg‐1·h‐1 dexmedetomidine combined with butorphanol (3 μg·kg‐1·h‐1)
Trial: 33628014
Drug: 0.05 μg·kg‐1·h‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 μg·kg‐1·h‐1 dexmedetomidine combined with butorphanol (3 μg·kg‐1·h‐1)
Trial: 33628014
Drug: 0.08 μg·kg‐1·h‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.08 μg·kg‐1·h‐1 dexmedetomidine combined with butorphanol (3 μg·kg‐1·h‐1)
Trial: 33628014
Drug: 0.9% sodium
RxNorm normalized name: LMD with 0.9% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride combined with butorphanol (3 μg·kg‐1·h‐1)
Trial: 35442393
Drug: Digital health
RxNorm normalized name: MENS HEALTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital health intervention with gamification (virtual teams, points, levels for daily step goal achievement)
Trial: 35442393
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving daily feedback on goal attainment
Trial: 32986770
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (IVL)
Trial: 32986770
Drug: No intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intravenous lidocaine (Control)
Trial: 35384422
Drug: Fluvoxamine 100
RxNorm normalized name: fluvoxamine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine 100 mg twice daily for 10 days
Trial: 34348011
Drug: Relaxation techniques
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation techniques (diaphragmatic breathing, progressive muscular relaxation, autogenic training, guided imagery) for 8 weeks, with weekly sessions and daily practice (2 times/day) using a compact disk.
Trial: 34348011
Drug: Relaxation techniques
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation techniques (treatment group).
Trial: 33326929
Drug: Musical stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Musical stimulation (15 minutes once daily for 7 days using an MP3 player and headphones)
Trial: 33326929
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (silent headphones for 15 minutes once daily for 7 days)
Trial: 33043347
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment group (ornidazole + periodontal tissue regeneration)
Trial: 32960748
Drug: New glucose-lowering
RxNorm normalized name: biguanide blood glucose lower drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New glucose-lowering drug
Trial: 35248549
Drug: GB001 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GB001 40 mg
Trial: 35248549
Drug: GB001 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GB001 60 mg
Trial: 32172441
Drug: Internet-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based therapy for depressive symptoms
Trial: 35281318
Drug: 0.5 μg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 μg/mL dexmedetomidine combined with 0.075% ropivacaine
Trial: 35281318
Drug: 0 μg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 μg/mL dexmedetomidine combined with 0.075% ropivacaine
Trial: 35281318
Drug: 0.1 μg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 μg/mL dexmedetomidine combined with 0.075% ropivacaine
Trial: 35281318
Drug: 0.2 μg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 μg/mL dexmedetomidine combined with 0.075% ropivacaine
Trial: 35281318
Drug: 0.3 μg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 μg/mL dexmedetomidine combined with 0.075% ropivacaine
Trial: 35281318
Drug: 0.4 μg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 μg/mL dexmedetomidine combined with 0.075% ropivacaine
Trial: 32624244
Drug: Fluocinolone acetonide
RxNorm normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluocinolone acetonide insert (FAi) 0.2 μg/day
Trial: 32620212
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus ipilimumab for 4 injections followed by nivolumab alone (arms 1B and 4B)
Trial: 32620212
Drug: Tyrosine kinase
RxNorm normalized name: Protein-tyrosine kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitor (sunitinib or pazopanib at investigator's choice) (arms 2C and 3C)
Trial: 33123838
Drug: OPT‐A (integrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPT‐A (integrated family‐based outpatient treatment)
Trial: 33017651
Drug: Airways therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Airways therapy for OSA
Trial: 36385314
Drug: Caffeine (CAF)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF) 6 mg kg−1
Trial: 34448448
Drug: IgG antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG antibodies in primary school students
Trial: 34448448
Drug: IgG antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG antibodies in secondary school students
Trial: 34448448
Drug: IgG antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG antibodies in household members
Trial: 35780195
Drug: Ventilatory settings
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ventilatory settings (median tidal volume 7 mL/PBW, PEEP 7 cmH20, plateau pressure 20 cmH20, driving pressure 12 cmH20, mechanical power 16.2 J/min, ventilatory ratio 1.27, respiratory rate 17 breaths/min)
Trial: 32281410
Drug: Antenatal education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal education (two 2-hr sessions twice a week for 4 weeks)
Trial: 32091467
Drug: Sham ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham ultrasound therapy (CON, n = 16)
Trial: 33177393
Drug: 1% benvitimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% benvitimod cream
Trial: 33177393
Drug: 1% benvitimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% benvitimod cream (retreatment)
Trial: 39033766
Drug: Cream vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream vehicle
Trial: 34218046
Drug: Subcutaneous hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous hydrocortisone
Trial: 36360666
Drug: Intralesional triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional triamcinolone acetonide injection, periodontal scaling, and oral hygiene instruction (experimental group)
Trial: 36360666
Drug: Intralesional triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional triamcinolone acetonide injection (control group)
Trial: 35681097
Drug: Lactoferrin 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactoferrin 100 mg/day for 3 months
Trial: 35681097
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate 6 mg/kg/day for 3 months
Trial: 33736484
Drug: Standard weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard weekly coaching sessions (Control)
Trial: 32434498
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of autologous adipose tissue
Trial: 33880752
Drug: Lactiplantibacillus plantarum
RxNorm normalized name: Lactiplantibacillus plantarum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactiplantibacillus plantarum 299v (Lp299v, 1010 colony forming units), 4.2 mg iron, 12 mg ascorbic acid and 30 µg folic acid (Lp)
Trial: 36104105
Drug: Music therapy-led
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy-led breathing exercises for 6 weeks
Trial: 34173669
Drug: RCTs involving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCTs involving any type of systemic therapy